LRRK2 and Parkinson disease: To follow up on this, future larger-scale studies including patients with monogenic forms of PD or who carry strong risk factors (e.g., LRRK2-PD, GBA1-PD, or PRKN/PINK1-PD), are important to target the effect of anti-inflammatory lifestyle factors on PD AAO.